Silence Therapeutics initiated with an Equal Weight at Morgan Stanley

Morgan Stanley analyst Andrew Galler initiated coverage of Silence Therapeutics with an Equal Weight rating and $18 price target. The analyst believes both the company’s core programs have the potential to be significant commercial opportunities. However, driving commercialization against larger peers "remains a key risk," Galler tells investors in a research note.